First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM
YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's first in vivo genome editing candidate being...
YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's first in vivo genome editing candidate being...
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)...